ClinicalTrials.gg
CompletedNCT00671749Updated Aug 23, 2022Results posted

Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris

A Phase 4 interventional study of adapalene gel, 0.3% and clindamycin/benzoyl peroxide gel in Acne Vulgaris, sponsored by Galderma R&D. Completed at 4 sites in United States. Open to participants aged 12 Years to 35 Years. Per ClinicalTrials.gov, last updated 2022-08-23.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
12 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing clindamycin in Acne Vulgaris — 1 open to participants now, 2 under way, none of them phase 3. Clindamycin · Acne Vulgaris.

Enrollment
18th of 34
100 · median 117
Started
2007
with 1 other
Phase 4
16 of 34
1 open now
Registered
4th of 34
by date
Lead sponsor
1 of 34
Galderma R&D

Among the 34 studies testing clindamycin in Acne Vulgaris, this one is the 18th largest by enrollment, is one of 2 that started in 2007, is one of 16 in phase 4, and was the 4th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

1 of the 34 studies testing clindamycin in Acne Vulgaris is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About clindamycin

Clindamycin: first FDA approval 1970 (CLEOCIN HYDROCHLORIDE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 12 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing clindamycin in Acne Vulgaris, or all of them as a file.
02

Study summary

This study is to determine the efficacy and safety of 12 week treatment with Differin® Gel 0.3% applied in the evening, in combination with Duac® (Clindamycin/Benzoyl Peroxide Gel) applied in the morning, in Subjects with Acne vulgaris.

Read the detailed description

Same as above.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

04

Who can participate

Ages eligible
12 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects with a minimum of 20 inflammatory lesions on the face;
  2. Subjects with a minimum of 15 and a maximum of 100 non-inflammatory lesions (open and closed comedones) on the face, excluding the nose;
  3. Subject has a Global Severity Assessment

Exclusion criteria

Exclusion Criteria:

  1. Subjects with more than three nodulo-cystic lesions
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Study Treatment

    adapalene gel, 0.3% Other Names: Differin® Gel, 0.3% Applied once daily at bedtime clindamycin/benzoyl peroxide gel Other Names: Duac® Gel Applied once daily in the morning

    Drug: adapalene gel, 0.3% · Drug: clindamycin/benzoyl peroxide gel

Interventions

  • Drugadapalene gel, 0.3%

    Applied once daily at bedtime

    Also known as: Differin® Gel, 0.3%

  • Drugclindamycin/benzoyl peroxide gel

    Drug pages: Clindamycin · Benzoyl Peroxide

    Applied once daily in the morning

    Also known as: Duac® Gel

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Total Lesion Counts

    Time frame: 6 and 12 weeks

Secondary outcomes

  1. Global Severity Assessment Success

    Global Severity was assessed on a 6 point scale (Clear, Almost Clear, Mild, Moderate, Severe). The scale was dichotomized to success or failure where success = Clear or Almost Clear

    Time frame: 6 and 12 weeks

  2. Global Assessment of Improvement From Baseline

    Time frame: 12 weeks

  3. Worst Post Baseline Tolerability Assessment - Erythema

    Please Note: "Tolerability Assessments" were captured separately from adverse events. Tolerability changes that required a dose modification or concomitant treatment were to be recorded on the Adverse Event CRF.

    Time frame: 12 weeks

  4. Worst Post Baseline Tolerability Assessment - Scaling

    Please Note: "Tolerability Assessments" were captured separately from adverse events. Tolerability changes that required a dose modification or concomitant treatment were to be recorded on the Adverse Event CRF.

    Time frame: 12 weeks

  5. Worst Post Baseline Tolerability Assessment - Dryness

    Please Note: "Tolerability Assessments" were captured separately from adverse events. Tolerability changes that required a dose modification or concomitant treatment were to be recorded on the Adverse Event CRF.

    Time frame: 12 weeks

  6. Worst Post Baseline Tolerability Assessment - Burning/Stinging

    Please Note: "Tolerability Assessments" were captured separately from adverse events. Tolerability changes that required a dose modification or concomitant treatment were to be recorded on the Adverse Event CRF.

    Time frame: 12 weeks

07

Results

Posted Mar 16, 2016

Participant flow

Participant flow — Overall Study
MilestoneCombination Therapy
Started100
Completed92
Not completed8
Withdrew: Adverse event2
Withdrew: Withdrawal by subject4
Withdrew: Protocol violation1
Withdrew: Lost to follow-up1

Outcome measures

PrimaryPercent Change From Baseline in Total Lesion Counts
Time frame:
6 and 12 weeks
Reported as:
Mean · Percent Change
Percent Change From Baseline in Total Lesion Counts
Percent ChangeCombination Therapy
Week 6-47 ± 24.43
Week 12-64 ± 24.07
SecondaryGlobal Severity Assessment Success

Global Severity was assessed on a 6 point scale (Clear, Almost Clear, Mild, Moderate, Severe). The scale was dichotomized to success or failure where success = Clear or Almost Clear

Time frame:
6 and 12 weeks
Reported as:
Number · participants
Global Severity Assessment Success
participantsCombination Therapy
Week 68
Week 1242
SecondaryGlobal Assessment of Improvement From Baseline
Time frame:
12 weeks
Reported as:
Number · participants
Global Assessment of Improvement From Baseline
participantsCombination Therapy
Clear3
Almost Clear40
Marked Improvement27
Moderate Improvement16
Minimal Improvement5
No Change8
Worse1
SecondaryWorst Post Baseline Tolerability Assessment - Erythema

Please Note: "Tolerability Assessments" were captured separately from adverse events. Tolerability changes that required a dose modification or concomitant treatment were to be recorded on the Adverse Event CRF.

Time frame:
12 weeks
Reported as:
Number · participants
Worst Post Baseline Tolerability Assessment - Erythema
participantsCombination Therapy
None29
Mild37
Moderate33
Severe0
SecondaryWorst Post Baseline Tolerability Assessment - Scaling

Please Note: "Tolerability Assessments" were captured separately from adverse events. Tolerability changes that required a dose modification or concomitant treatment were to be recorded on the Adverse Event CRF.

Time frame:
12 weeks
Reported as:
Number · participants
Worst Post Baseline Tolerability Assessment - Scaling
participantsCombination Therapy
None53
Mild27
Moderate16
Severe3
SecondaryWorst Post Baseline Tolerability Assessment - Dryness

Please Note: "Tolerability Assessments" were captured separately from adverse events. Tolerability changes that required a dose modification or concomitant treatment were to be recorded on the Adverse Event CRF.

Time frame:
12 weeks
Reported as:
Number · participants
Worst Post Baseline Tolerability Assessment - Dryness
participantsCombination Therapy
None49
Mild27
Moderate20
Severe3
SecondaryWorst Post Baseline Tolerability Assessment - Burning/Stinging

Please Note: "Tolerability Assessments" were captured separately from adverse events. Tolerability changes that required a dose modification or concomitant treatment were to be recorded on the Adverse Event CRF.

Time frame:
12 weeks
Reported as:
Number · participants
Worst Post Baseline Tolerability Assessment - Burning/Stinging
participantsCombination Therapy
None67
Mild18
Moderate9
Severe5

Adverse events

Collected over 12 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Combination Therapy—0/99 (0%)32/99 (32.3%)
Most frequent other events
Most frequent other events
EventCombination Therapy
Application Site BurnGeneral disorders32/99
Application Site DrynessGeneral disorders24/99
Application Site ErythemaGeneral disorders10/99
Application Site ExfoliationGeneral disorders7/99
Application Site DiscomfortGeneral disorders6/99

Baseline characteristics

Age, Continuous
Age, Continuous(years)Combination Therapy
Mean18.2 ± 5.40
Sex: Female, Male
Sex: Female, Male(Participants)Combination Therapy
Female56
Male44
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Combination Therapy
American Indian or Alaska Native1
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American10
White77
More than one race10
Unknown or Not Reported0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Combination Therapy
Hispanic or Latino7
Not Hispanic or Latino93
Unknown or Not Reported0
Duration of Acne
Duration of Acne(years)Combination Therapy
Mean4.0 ± 3.91
Fitzpatrick Skin Type
Fitzpatrick Skin Type(participants)Combination Therapy
I1
II27
III38
IV22
V4
VI8
08

Study locations

4 sites
  • Center for Dermatology and Laser Surgery
    Sacramento, California 95819, United States
  • Derm Research, P.L.L.C.
    Louisville, Kentucky 40217, United States
  • Brodell Medical
    Warren, Ohio 44483, United States
  • Northwest Cutaneous Research Specialists
    Portland, Oregon 97210, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2007, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2016, 7 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2008
First posted
May 5, 2008
Start
Dec 2007
Primary completionActual
Aug 2008
CompletionActual
Aug 2008
Results first posted
Mar 16, 2016
Last update
Aug 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00671749
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
May 5, 2008
Start date
Dec 2007
Primary completion
Aug 2008
Completion
Aug 2008
Results posted
Mar 16, 2016
Last update
Aug 23, 2022

Study contacts

Ron W Gottschalk, MD
study director · Galderma R&D

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Clindamycin · Benzoyl Peroxide

Start the discussion